Rebecca Maxwell
Nurse Practitioner · Cincinnati, OHNPI 1235757238
Payments from drug & device makers
Across 243 payments — averaging $25.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$1K
- Sanofi$823
- Regeneron Healthcare Solutions, Inc.$643
- Grifols USA, LLC$287
- Boehringer Ingelheim$262
- plus $1K from 24 others
What the payments were for
- Consulting fees$90015%
- Food & beverage$5,07683%
- Education$1532%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 36 | $1,493 |
| AstraZeneca | 38 | $1,142 |
| Sanofi | 53 | $823 |
| Regeneron Healthcare Solutions, Inc. | 31 | $643 |
| Grifols USA, LLC | 20 | $287 |
| Boehringer Ingelheim | 10 | $262 |
| Inspire Medical Systems, Inc. | 3 | $212 |
| Sanofi-aventis U.S. LLC | 2 | $153 |
| Harmony Biosciences LLC | 3 | $107 |
| Electromed, Inc. | 7 | $107 |
| Amgen | 4 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $85 |
| Axsome Therapeutics, Inc. | 3 | $79 |
| Philips North America LLC | 3 | $76 |
| Merck | 3 | $69 |
| Bayer | 3 | $67 |
| United Therapeutics Corporation | 2 | $51 |
| Verona Pharma, Inc. | 2 | $48 |
| Mallinckrodt Hospital Products Inc. | 2 | $41 |
| Baxter Healthcare | 2 | $37 |
| Pulmonx Corporation | 2 | $36 |
| Liquidia Technologies, Inc. | 1 | $34 |
| Genentech USA, Inc. | 2 | $33 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $33 |
| Mylan Specialty L.p. | 1 | $25 |
| Insmed, Inc. | 1 | $21 |
| Novartis | 1 | $21 |
| Lilly USA, LLC | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Inogen, Inc. | 2 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,129 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 319 | $293,991 |
| Dupixent PenDupilumab | 26 | $98,542 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 95 | $64,362 |
| Fasenra PenBenralizumab | 11 | $63,533 |
| Spiriva RespimatTiotropium Bromide | 74 | $58,730 |
| Breo ElliptaFluticasone/Vilanterol | 91 | $46,078 |
| Advair HfaFluticasone Propion/Salmeterol | 67 | $31,055 |
| EliquisApixaban | 33 | $28,047 |
| SymbicortBudesonide/Formoterol Fumarate | 73 | $24,904 |
| DuleraMometasone/Formoterol | 51 | $20,131 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 116 | $19,487 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $15,547 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $15,072 |
| Spiriva HandihalerTiotropium Bromide | 11 | $11,447 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $8,483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,493 | $368,713472 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $1,142 | $92,199180 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $262 | $73,80290 claims |
| MerckDulera | $69 | $20,13151 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in Cincinnati
- Sonia HissettCincinnati$179K
- Tiffany JonesCincinnati$99K
- Jolyn MorganCincinnati$17K
- Sandra ParawiraCincinnati$10K
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
- Katherine AlexanderColumbus$99K
- Kate NewmanWestlake$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.